Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Idun the Latest to Seek Shelter via Pfizer's M&A Highway

This article was originally published in Start Up

Executive Summary

In February, Idun Pharmaceuticals became the fourth company acquired by Pfizer in the last 15 months. While those transactions reflect different mixes of product and technology breadth, they suggest a greater alignment between the interests of some private biotechs, their investors, and potential pharma company acquirers, as well as an evolution in the deal calculus for choosing M&A over an alliance or IPO.

You may also be interested in...



Roche Opens NY R&D Hub As Its pRED Head Vows To Boost Alliances

Amid a day of celebrations around the long-awaited opening of its translational and clinical research center in New York, Roche’s new head of research and early development, the superstar scientist John Reed, offered a glimpse of how the organization is restructuring its external relationships and its priorities going forward.

UCSF Spinout Calithera Biosciences Takes $40 Million First Round

The cancer-fighting drug researcher is developing methods of activating caspases, enzymes that induce programmed cell death.

UCSF Spinout Calithera Biosciences Takes $40 Million First Round

The cancer-fighting drug researcher is developing methods of activating caspases, enzymes that induce programmed cell death.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

SC091067

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel